5 completed, 1 terminated. 5 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 4, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow Stage IV Hypopharyngeal Squamous Cell Carcinoma: new trials by email Literature Review of Stage IV Hypopharyngeal Squamous Cell Carcinoma trials Research Report on Stage IV Hypopharyngeal Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Paclitaxel, Carboplatin, Nivolumab - Name Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 34 | 2017-11-13 | 2025-04-24 |
| Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer Communication Intervention, Watch video, Module completion of the Prepare to Care kit - Caregiver, Malignant Head and Neck Neoplasm | Not applicable | Completed | Wake Forest University Health Sciences | 35 | 2017-05-15 | 2023-01-09 |
| Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 6 | 2014-03-01 | 2017-05-03 |
| Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy Cetuximab, Laboratory Biomarker Analysis, Temsirolimus - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 86 | 2010-11-01 | 2017-03-27 |
| Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery Laboratory Biomarker Analysis, Soy Isoflavones, Survey Administration - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2016-10-24 |
| Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer Cediranib Maleate, Laboratory Biomarker Analysis - Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2007-02-01 | 2015-05-05 |
Squamous Cell Carcinoma of Head and Neck (6) · Lymphoid Interstitial Pneumonia (5) · Tongue Neoplasms (4) · Salivary Gland Neoplasms (2) · Head and Neck Neoplasms (1)
Carcinoma (6) · Carcinoma, Squamous Cell (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Head and Neck Neoplasms (5) · Mouth Diseases (4) · Mouth Neoplasms (4) · Stomatognathic Diseases (4) · Tongue Diseases (4) · Salivary Gland Diseases (2)
1,2-diaminocyclohexaneplatinum II citrate (1) · Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Educational Status (1) · Methods (1) · Nivolumab (1) · Paclitaxel (1) · Platinum (1) · Sirolimus (1) · Soybean Proteins (1) · Taxes (1) · adavosertib (1) · cediranib (1) · temsirolimus (1)
National Cancer Institute (NCI) (4) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Wake Forest University Health Sciences (1)
United States (5) · Canada (1) · China (1)
Chandylen Nightingale (1) · Eric Winquist (1) · Greg Wolf (1) · James Rocco (1) · Jennifer Johnson, MD, PhD (1) · Tanguy Seiwert (1)
N01CM00032 (1), N01CM00071 (1), N01CM00099 (1), N01CM62201 (1), P30CA006516 (1), P30CA012197 (1), P30CA014599 (1), P30CA046592 (1), R03CA208560 (1), R21CA119591 (1)